News

Applied Clinical Trials Online23h

Response’s Investigational Small Molecule Inhibitor Shows Promising Post-GLP-1 Weight Management, Cardiometabolic Benefits

Results from a Phase II trial (NCT06640972) showed that patients treated with RDX-002 experienced significant reductions in ...
The Pharma Letter6h

Response offers positive Phase II data for post-GLP-1 obesity

US biotech Response Pharmaceuticals (Nasdaq: RSPN) has unveiled top-line Phase II results for its experimental obesity ...